CN104447817B - 一种配合物[[Cu2(L7)(L10)]的原位合成及作为抗癌药物的应用 - Google Patents
一种配合物[[Cu2(L7)(L10)]的原位合成及作为抗癌药物的应用 Download PDFInfo
- Publication number
- CN104447817B CN104447817B CN201410800284.2A CN201410800284A CN104447817B CN 104447817 B CN104447817 B CN 104447817B CN 201410800284 A CN201410800284 A CN 201410800284A CN 104447817 B CN104447817 B CN 104447817B
- Authority
- CN
- China
- Prior art keywords
- coordination compound
- chloropyridine
- analytical pure
- cell
- oxygen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 28
- 239000003814 drug Substances 0.000 title claims abstract description 17
- 229940079593 drug Drugs 0.000 title claims abstract description 10
- 238000011065 in-situ storage Methods 0.000 title claims abstract description 10
- 238000011275 oncology therapy Methods 0.000 title claims abstract description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims abstract description 15
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000010949 copper Substances 0.000 claims abstract description 15
- 239000000243 solution Substances 0.000 claims abstract description 11
- 229960003328 benzoyl peroxide Drugs 0.000 claims abstract description 5
- SXTLQDJHRPXDSB-UHFFFAOYSA-N copper;dinitrate;trihydrate Chemical compound O.O.O.[Cu+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O SXTLQDJHRPXDSB-UHFFFAOYSA-N 0.000 claims abstract description 5
- 238000002425 crystallisation Methods 0.000 claims abstract description 5
- 230000008025 crystallization Effects 0.000 claims abstract description 5
- 239000000706 filtrate Substances 0.000 claims abstract description 5
- 239000011259 mixed solution Substances 0.000 claims abstract description 5
- 229950000845 politef Drugs 0.000 claims abstract description 5
- 238000010189 synthetic method Methods 0.000 claims description 5
- 239000013078 crystal Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 abstract description 8
- 239000000470 constituent Substances 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 45
- 210000004027 cell Anatomy 0.000 description 41
- 210000004881 tumor cell Anatomy 0.000 description 15
- 239000012531 culture fluid Substances 0.000 description 12
- 230000001629 suppression Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 9
- 244000309466 calf Species 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 230000003287 optical effect Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 231100000263 cytotoxicity test Toxicity 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 3
- 206010005003 Bladder cancer Diseases 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 239000013553 cell monolayer Substances 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 3
- 229960004316 cisplatin Drugs 0.000 description 3
- 239000006184 cosolvent Substances 0.000 description 3
- 239000012738 dissolution medium Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 201000005249 lung adenocarcinoma Diseases 0.000 description 3
- 201000005296 lung carcinoma Diseases 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 201000005112 urinary bladder cancer Diseases 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
- C07F1/08—Copper compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
BEL-7404 | HepG2 | NCI-H460 | T-24 | A549 | HL-7702 | |
[Cu2(L7)(L10)] | 48.65±1.51 | 30.78±1.55 | 25.08±0.41 | 39.61±0.62 | 17.55±1.45 | 24.12±0.97 |
顺铂 | 55.15±1.18 | 60.63±0.99 | 50.88±3.69 | 47.58±2.65 | 60.63±0.99 | 73.58±2.30 |
BEL-7404 | HepG2 | NCI-H460 | T-24 | A549 | HL-7702 | |
[Cu2(L7)(L10)] | 20.13±1.36 | 85.75±1.64 | 78.15±0.75 | 41.54±0.58 | 153.34±1.73 | 126.28±0.84 |
顺铂 | 12.41±0.38 | 9.48±0.35 | 18.89±1.02 | 28.07±1.88 | 9.48±0.35 | 5.63±0.32 |
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410800284.2A CN104447817B (zh) | 2014-12-19 | 2014-12-19 | 一种配合物[[Cu2(L7)(L10)]的原位合成及作为抗癌药物的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410800284.2A CN104447817B (zh) | 2014-12-19 | 2014-12-19 | 一种配合物[[Cu2(L7)(L10)]的原位合成及作为抗癌药物的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104447817A CN104447817A (zh) | 2015-03-25 |
CN104447817B true CN104447817B (zh) | 2016-06-29 |
Family
ID=52894631
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410800284.2A Expired - Fee Related CN104447817B (zh) | 2014-12-19 | 2014-12-19 | 一种配合物[[Cu2(L7)(L10)]的原位合成及作为抗癌药物的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104447817B (zh) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103319506B (zh) * | 2013-07-05 | 2015-12-23 | 桂林理工大学 | 一种[Cu2(L3)2]的原位合成方法 |
CN103319507B (zh) * | 2013-07-05 | 2015-12-23 | 桂林理工大学 | 一种[Cu2(L2)2](C2H3N)2的原位合成方法 |
CN103524536A (zh) * | 2013-10-20 | 2014-01-22 | 桂林理工大学 | [Cu2(L4)2]·(CH3OH)配合物及合成方法 |
CN103819453A (zh) * | 2014-02-19 | 2014-05-28 | 桂林理工大学 | 一种[Cu2(L2)2]·H2O配合物及原位合成方法 |
CN103880870A (zh) * | 2014-04-05 | 2014-06-25 | 桂林理工大学 | 一种配合物[Cu2(L8)(L9)]·(C3H7OH)·(H2O)及原位合成方法 |
CN103880818A (zh) * | 2014-04-05 | 2014-06-25 | 桂林理工大学 | 一种抗癌药物[Cu2(L7)2]·(CH3CH2OH)2 |
CN103880869A (zh) * | 2014-04-05 | 2014-06-25 | 桂林理工大学 | 一种抗癌药物[Cu2(L4)(L6)]及其原位合成方法 |
-
2014
- 2014-12-19 CN CN201410800284.2A patent/CN104447817B/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN104447817A (zh) | 2015-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103450236A (zh) | 6-羟基氧化异阿朴啡稀土配合物及其合成方法和应用 | |
CN109897071A (zh) | 一种以2-吡啶甲醛缩氨基硫脲为配体的铂配合物及其合成方法和应用 | |
CN104610372A (zh) | 以2-苯甲酰基吡啶为配体的铂(ii)配合物的合成方法和应用 | |
CN104804046A (zh) | 一种铂(ii)配合物及其合成方法和应用 | |
CN103524564A (zh) | 一种6-氨基氧化异阿朴啡的铂(ii)配合物合成方法和应用 | |
CN109796497A (zh) | 一种以2-乙酰基-3-乙基吡嗪缩氨基硫脲为配体的铋化合物及其合成方法 | |
CN104557887A (zh) | 一种1,8-萘二甲酰亚胺衍生物及其合成方法和应用 | |
CN104910196B (zh) | 一种手性四核铜基有机金属框架及其制备方法和应用 | |
CN104447817B (zh) | 一种配合物[[Cu2(L7)(L10)]的原位合成及作为抗癌药物的应用 | |
CN104610373A (zh) | 一种以三联吡啶衍生物为配体的铂(ii)配合物及合成方法和应用 | |
CN104649930B (zh) | 具抗癌活性的配合物[Zn(H2L4)2].(H2O)的合成及应用 | |
CN105693636A (zh) | 具抗癌活性的Cu(mtyp)2的合成及应用 | |
CN104650121A (zh) | 具抗癌活性的配合物[Zn(H2L2)2](H2O)5的合成及应用 | |
CN104447766A (zh) | 一种配合物[Cu2(L12)2]·(H2O)的原位合成及抗肿瘤应用 | |
CN103421048A (zh) | 一氯·二甲基亚砜·6-羟基氧化异阿朴啡合铂(ii)及其合成方法和应用 | |
CN107417708B (zh) | 一种水溶性铜(ii)配合物及其合成方法和应用 | |
CN107488198B (zh) | 一种色胺酮铂配合物及其合成方法与应用 | |
CN106632328B (zh) | 一种具有抗肿瘤活性的吴茱萸碱铜盐化合物及其合成方法 | |
CN104530098A (zh) | 单晶级[Cu2(L11)2]·(H2O)配合物的合成方法及作为抗癌药物应用 | |
CN109627210B (zh) | 一种镓荧光探针及其制备方法、应用和应用产物 | |
CN104650157A (zh) | 具抗癌活性的配合物[Ni(H2L2)2](H2O)2的合成及应用 | |
CN109666047B (zh) | 一种钌荧光探针及其制备方法、应用和应用产物 | |
CN104447397B (zh) | 具抗癌活性的3,5-二溴水杨醛缩2-氨基-2-甲基-1,3-丙二醇希夫碱的合成及应用 | |
CN104530099A (zh) | 配合物[Cu2(L13)(L14)]·(CH3OH)的原位合成方法及抗肿瘤应用 | |
CN104387423A (zh) | 以手性化合物为配体的铂(ii)配合物及其合成方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210112 Address after: 510000 room 2108, No.1 Industrial Avenue, high tech Industrial Park, Conghua Economic Development Zone, Guangzhou City, Guangdong Province (office use only) Patentee after: Bofan software (Guangzhou) Co.,Ltd. Address before: 541004 the Guangxi Zhuang Autonomous Region Guilin Construction Road No. 12 Patentee before: GUILIN University OF TECHNOLOGY |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160629 Termination date: 20211219 |